证券代码：603259 证券简称：药明康德 公告编号：临 2023-055 无锡药明康德新药开发股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已于 2023 年 8 月 1 日在上海证券交易所网站（www.sse.com.cn）及指定媒体披露《无锡药明康 德新药开发股份有限公司 2023 年半年度报告》。为了便于广大投资者更全面深入 地了解本公司 2023 年半年度业绩和经营情况，本公司拟于 2023 年 8 月 23 日（星 期三）上午 10:30-11:30 召开业绩说明会，就投资者普遍关心的问题进行交流。 一、 业绩说明会类型 本次业绩说明会以视频结合网络互动方式召开，本公司将针对 2023 年半年 度业绩和经营情况与投资者进行交流，并在信息披露允许的范围内就投资者普遍 关注的问题进行回答。 二、 业绩说明会召开的时间、地点 会议召开时间：2023 年 8 月 23 日（星期三）上午 10: ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-054 无锡药明康德新药开发股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、减持主体的基本情况 注：上述持股比例按照公司截至 2023 年 8 月 7 日的总股本 2,968,448,145 股 1 为基础计算。 重要内容提示： 股东持股的基本情况 截至本公告披露日，无锡药明康德新药开发股份有限公司（以下简称"公司"） 股东 Summer Bloom Investments (I) Pte. Ltd.持有公司 A 股股份 159,160,073 股， 占公司截至 2023 年 8 月 7 日总股本的 5.36%，该等股份为其于公司 IPO 前取得 的股份和上市后通过公司权益派发资本公积转增股本取得的股份。 减持计划的主要内容 公司于 2023 年 8 月 8 日收到股东 Summer Bloom Investments (I) Pte. Ltd.发出 的《减持计划告知函》。因基金投资正常退出，Summer Bl ...

Financial Performance - The company reported a total revenue of RMB 5.2 billion for the first half of 2023, representing a year-on-year increase of 15%[2]. - The gross profit margin for the first half of 2023 was 35%, compared to 32% in the same period last year[2]. - The company reported a net profit of RMB 1.1 billion for the first half of 2023, reflecting a net profit margin of 21%[2]. - The management has set a revenue target of RMB 12 billion for the full year 2023, which would represent a growth of 20% compared to 2022[2]. - Net profit attributable to shareholders of the listed company increased by 14.61% year-on-year, reaching RMB 5,313,119,704.09[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses grew by 23.67% year-on-year, amounting to RMB 4,761,082,555.91[18]. - Basic earnings per share for the first half of 2023 were RMB 1.81, up 13.84% from RMB 1.59 in the same period last year[17]. - Diluted earnings per share increased by 20.95% to RMB 1.79, compared to RMB 1.48 in the previous year[17]. - The company's total assets reached RMB 69,319,133,730.68, a 7.16% increase from the end of the previous year[16]. - The net cash flow from operating activities was RMB 5,598,180,734.15, reflecting a significant increase of 40.10% compared to the previous year[18]. Client and Market Growth - The number of active clients increased to 1,200, up from 1,050 in the previous year, indicating a growth of approximately 14.3%[2]. - Revenue from the top 20 global pharmaceutical companies accounted for approximately 38% of total revenue, with a year-on-year growth of 47% when excluding specific commercial production projects[28]. - The company served over 6,000 active clients in the past 12 months, with new client additions exceeding 600 during the first half of 2023[29]. - The company continues to drive revenue growth through its unique CRDMO and CTDMO business models[18]. Research and Development - The company plans to expand its R&D capabilities with an investment of RMB 1 billion in new technologies and facilities over the next two years[2]. - The company is focusing on the development of innovative drugs, with 15 new drug candidates currently in the pipeline[2]. - The company aims to enhance its service capabilities in new molecular types such as PROTAC, oligonucleotide drugs, peptide drugs, and antibody-drug conjugates, to capture new business opportunities[26]. - The company is positioned to benefit from the increasing outsourcing rates in the pharmaceutical industry, particularly from small and medium-sized biotech firms seeking integrated development services[25]. Environmental Initiatives - The company is committed to sustainability and has implemented new environmental initiatives aimed at reducing carbon emissions by 30% by 2025[2]. - The company reported a total of 33,488.665 tons of hazardous waste collected and disposed of by qualified third parties[83]. - The company has engaged third-party qualified entities for the disposal of hazardous waste, ensuring proper environmental management practices[81]. - The company has implemented measures to reduce emissions of non-methane total hydrocarbons, with a reported emission of 3.142 tons annually[81]. - The company has established a waste management program to oversee the handling of general industrial solid waste and hazardous solid waste, ensuring compliance with national regulations[96]. Risk Management - The company has identified potential risks related to regulatory changes and market competition, which may impact future performance[2]. - The company faced risks related to a potential decline in demand for pharmaceutical R&D services, which could adversely affect business performance[57]. - The company is exposed to regulatory risks in the pharmaceutical R&D services industry, which could impact operations if not managed properly[58]. - The company has established a comprehensive internal control system to ensure compliance with national laws and regulations, but risks remain due to the number of subsidiaries and potential regulatory oversight failures[60]. Corporate Governance - The company elected Ge Li as the chairman and CEO, and Edward Hu as the vice chairman and global chief investment officer during the board meeting on June 6, 2023[74]. - The third supervisory board was elected, with Harry Liang He as the chairman, confirmed during the meeting on June 6, 2023[75]. - The company held its annual general meeting on May 31, 2023, where the third board of directors and supervisors were elected[73]. - The company has not made any progress or changes regarding its stock incentive plan since the last announcement[77]. Shareholder Commitments - The actual controller committed to reducing shareholding within two years after the lock-up period, ensuring the selling price will not be lower than the issuance price, adjusted for rights issues[172]. - The company has established rules for share reduction, including a maximum of 1% of total shares in any 90-day period for centralized bidding transactions[173]. - The commitment also states that any share reduction must be disclosed 15 trading days in advance for centralized bidding transactions[172]. - The actual controller has promised to avoid the misuse of rights to occupy the company's funds and assets, ensuring compliance with relevant laws and regulations[184]. Employee Engagement - The company employs a total of 41,296 staff, with 12,520 holding master's degrees or higher, and 1,374 holding doctoral degrees[22]. - The company continues to focus on stock incentive plans to align employee interests with shareholder value[200]. - The company’s stock incentive plans include multiple phases of restricted share releases, indicating ongoing employee engagement strategies[200].

Financial Performance - The company achieved revenue of RMB 18,871.3 million for the six months ended June 30, 2023, representing a year-on-year growth of 6.3%[4] - Net profit attributable to the parent company was RMB 5,313.1 million, an increase of 14.6% compared to the same period in 2022[4] - The adjusted net profit attributable to the parent company was RMB 5,094.7 million, reflecting an 18.5% year-on-year growth[4] - The company achieved a gross profit of RMB 7.56 billion, representing a year-on-year increase of 17.6%, with a gross margin of 40.0%[15] - The total comprehensive income for the period was RMB 4,843,228 thousand, compared to RMB 4,377,071 thousand in the same period of 2022, reflecting an increase of approximately 10.6%[90] - The company reported a significant increase in tax payable to RMB 819.1 million, up 58.2% due to increased taxable profits from subsidiaries during the reporting period[34] - The company reported a significant increase in accounts receivable and other receivables, which rose to RMB 9,237,398 thousand from RMB 7,590,361 thousand, reflecting an increase of about 21.7%[91] Revenue Breakdown - Revenue from U.S. clients reached RMB 12.37 billion, a 42% increase year-on-year when excluding COVID-19 commercialization projects[4] - Revenue from the top 20 global pharmaceutical companies was RMB 7.14 billion, showing a strong growth of 47% when excluding COVID-19 commercialization projects[5] - The WuXi Chemistry segment generated revenue of RMB 13,467.2 million, a 3.8% increase year-on-year[6] - The WuXi Testing segment reported revenue of RMB 3,091.0 million, reflecting an 18.7% year-on-year growth[8] - The TIDES business revenue reached RMB 1.33 billion, with a year-on-year growth of 37.9%[7] - Clinical CRO and SMO achieved revenue of RMB 850 million, a year-on-year increase of 18.3%, with SMO business revenue growing by 34.3%[9] - The biology segment generated revenue of RMB 1.23 billion, reflecting a year-on-year growth of 13.0%, with new molecular-related revenue increasing by 51%[10] Client Growth and Market Presence - The company added over 600 new clients in the first half of 2023, with active clients exceeding 6,000 over the past 12 months[4] - The company’s services to the top 20 global pharmaceutical companies accounted for approximately 38% of total revenue during the reporting period[47] - The early discovery platform contributed over 20% of new customers in the first half of 2023, serving over 1,600 clients with a compound library exceeding 90 billion molecules[10] Financial Position and Cash Flow - Net cash generated from operating activities was RMB 5,340.7 million for the six months ended June 30, 2023, an increase of 41.7% compared to RMB 3,767.9 million for the same period in 2022[23] - Net cash used in investing activities decreased by 65.3% to RMB 1,307.8 million for the six months ended June 30, 2023, primarily due to timing differences in capital expenditures[24] - Total liabilities as of June 30, 2023, were RMB 19,120.4 million, up from RMB 17,763.7 million as of December 31, 2022[25] - The company's total borrowings amounted to RMB 4,422.1 million as of June 30, 2023, all of which were fixed-rate borrowings[26] - The debt-to-asset ratio as of June 30, 2023, was 27.6%, compared to 27.5% as of December 31, 2022, indicating a stable and healthy financial position[27] Strategic Investments and R&D - The company is preparing for the commercialization of CAR-T products, with production expected to start in the first half of 2024[11] - The company aims to enhance its service capabilities in new molecular types such as PROTAC, oligonucleotide drugs, and peptide drugs, to seize new business opportunities[44] - The company is committed to continuous investment in global capabilities and scale to empower pharmaceutical innovation[43] - The company continues to focus on research and development in small molecule drugs, cell therapy, and gene therapy, positioning itself for future growth in these sectors[93] Risks and Challenges - The company recognizes potential risks from declining demand in the pharmaceutical R&D service market, which could negatively impact business if outsourcing trends slow down[70] - The pharmaceutical R&D service industry is highly regulated, with potential adverse impacts on the company's operations if it fails to adapt to changes in industry policies and regulations[71] - The global pharmaceutical R&D service market is becoming increasingly competitive, with threats from both established players and new entrants that may possess stronger financial and technical capabilities[72] - The company's main business revenue is primarily denominated in USD, exposing it to risks from significant appreciation of the RMB, which could increase costs and reduce order volumes[78] Shareholder Information - A total of 131,328 restricted A-shares were released from restrictions under the 2018 A-share incentive plan, accounting for approximately 0.005% of the company's total issued A-shares[49] - The 2022 profit distribution plan was approved, with a cash dividend of RMB 8.9266 per 10 shares for shareholders listed on June 13, 2023[52] - The company completed the redemption of all outstanding zero-coupon convertible bonds amounting to $300 million on April 4, 2023[59] - The board did not recommend any interim dividend for the reporting period[82] Operational Enhancements - The company expanded its testing laboratory by 55,000 square meters during the reporting period, enhancing its capabilities and capacity[46] - The company is focused on enhancing its product offerings through continuous innovation and development of new technologies[132] - The company will maintain the highest international quality standards and continuously improve operational processes to ensure compliance and prevent accidents[66]

Financial Performance - The company's revenue for Q1 2023 was approximately ¥8.96 billion, representing a year-on-year increase of 5.77%[7] - Net profit attributable to shareholders for Q1 2023 was approximately ¥2.17 billion, reflecting a significant increase of 31.97% compared to the same period last year[7] - The net cash flow from operating activities reached approximately ¥3.03 billion, showing a remarkable increase of 508.55% year-on-year[7] - Total revenue for Q1 2023 reached ¥8,963,741,607.53, an increase of 5.8% compared to ¥8,474,419,333.59 in Q1 2022[28] - Operating profit for Q1 2023 was ¥2,615,354,834.65, up from ¥2,004,959,729.24 in Q1 2022, reflecting a growth of 30.5%[28] - Net profit for Q1 2023 was ¥2,185,804,643.61, compared to ¥1,655,950,521.89 in Q1 2022, representing a year-over-year increase of 31.9%[28] - The gross profit for Q1 2023 was ¥3,525,642,000, up from ¥3,014,848,000 in Q1 2022, which is an increase of approximately 17.0%[35] Assets and Liabilities - The total assets as of March 31, 2023, amounted to approximately ¥68.19 billion, an increase of 5.41% from the end of the previous year[8] - Total assets as of March 31, 2023, amounted to CNY 68,188,089 thousand, up from CNY 64,690,327 thousand at the end of 2022, indicating a growth of approximately 7%[38] - Total liabilities reached ¥18,357,086,099.46 as of March 31, 2023, compared to ¥17,763,654,011.21 at the end of 2022, showing an increase of 3.3%[26] - The total liabilities increased to CNY 18,357,086 thousand in Q1 2023 from CNY 17,763,654 thousand in Q4 2022, marking an increase of about 3.34%[39] - The company's equity attributable to shareholders increased to ¥49.47 billion, up by 6.19% compared to the end of the previous year[8] - The company's equity attributable to shareholders increased to CNY 49,474,883 thousand in Q1 2023 from CNY 46,589,953 thousand in Q4 2022, representing a growth of about 6%[39] Client and Market Activity - The company served over 6,000 active clients from more than 30 countries through its 32 operational bases as of the end of the reporting period[5] - The company added over 310 new clients, bringing the total active client count to over 6,000, indicating a sustained demand for services globally[12] - Revenue from existing clients accounted for 99% of total revenue, amounting to RMB 88.8 billion, a 7% increase year-on-year[12] - The company’s revenue from global top 20 pharmaceutical companies was RMB 31.5 billion, a 17% decline year-on-year, primarily due to project fluctuations[12] Business Segments Performance - The chemical business (WuXi Chemistry) generated RMB 643,278.20 million in revenue, up 5.1% year-on-year, with a 21.8% growth rate when excluding specific commercial projects[15][16] - The testing business (WuXi Testing) reported revenue of RMB 145,287.67 million, a 13.6% increase year-on-year, with laboratory analysis and testing services growing by 15.9%[16] - The biological business (WuXi Biology) achieved revenue of RMB 57,699.75 million, reflecting an 8.3% year-on-year growth, with new molecular-related services growing by 40%[17][18] - The CTDMO business (WuXi ATU) generated RMB 32,448.54 million, a year-on-year increase of 8.7%, with the cell and gene therapy testing business growing by 8.6%[18] Future Outlook - The company anticipates a revenue growth of 5-7% for the entire year of 2023, based on current order status and stable global pharmaceutical industry conditions[19] - Future revenue growth is expected to come primarily from drug sales revenue sharing, with a projected compound annual growth rate of around 50% over the next decade as more DDSU client drugs reach the market[19] Research and Development - Research and development expenses increased to ¥357,301,004.44 in Q1 2023, up from ¥280,042,477.39 in Q1 2022, marking a rise of 27.6%[28] - The company completed 3 IND applications and received 6 clinical trial approvals (CTA) in Q1 2023, with a total of 175 IND applications and 150 CTAs completed to date[19] - The company is working on 15 new molecular projects, including peptide-drug conjugates and oligonucleotides, with several IND applications expected to be submitted this year[19]

Financial Performance - The company reported a total revenue of RMB 8,963,741,607.53 for Q1 2023, representing a year-on-year increase of 5.77%[6] - Net profit attributable to shareholders reached RMB 2,168,128,379.15, marking a significant increase of 31.97% compared to the previous year[6] - The adjusted net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 1,868,816,896.68, reflecting a 9.02% increase year-on-year[6] - Basic earnings per share were RMB 0.74, up by 32.14% year-on-year, while diluted earnings per share were RMB 0.72, increasing by 35.85%[6] - Total comprehensive income for Q1 2023 was RMB 2.17 billion, up from RMB 1.65 billion in Q1 2022, marking a 31.6% increase[28] - Net profit for Q1 2023 was RMB 2.19 billion, up 31.8% from RMB 1.66 billion in Q1 2022[27] - Operating profit for Q1 2023 was RMB 2.62 billion, compared to RMB 2.00 billion in Q1 2022, reflecting a 30.6% increase[26] - The company reported a net profit of 2,168,129 thousand RMB for Q1 2023, compared to 1,642,947 thousand RMB in Q1 2022, which is an increase of about 32%[38] Cash Flow and Assets - The net cash flow from operating activities surged to RMB 3,027,329,258.18, an impressive increase of 508.55% compared to the same period last year[6] - Cash flow from operating activities for Q1 2023 was RMB 3.03 billion, significantly higher than RMB 497.47 million in Q1 2022[30] - The company incurred a net cash outflow from investing activities of RMB 1,222,881,147.89 in Q1 2023, contrasting with a net inflow of RMB 1,474,723,859.12 in Q1 2022[31] - The company’s financing activities generated a net cash inflow of RMB 148,902,292.20 in Q1 2023, down from RMB 387,302,550.67 in Q1 2022[31] - The company’s cash and cash equivalents increased to RMB 9,867,844,029.10 by the end of Q1 2023, up from RMB 7,983,904,283.09 at the beginning of the quarter[34] - The company's cash and cash equivalents increased to 9,867,844 thousand RMB by the end of Q1 2023, compared to 7,026,525 thousand RMB at the end of Q1 2022, marking a growth of about 40%[37] Revenue Breakdown - Revenue from the chemical business reached RMB 6,432.8 million, a 5.1% increase compared to RMB 6,118.0 million in the same period last year[12] - The testing business generated revenue of RMB 1,452.9 million, reflecting a year-on-year growth of 13.6%[13] - The biology business achieved revenue of RMB 577.0 million, an increase of 8.3% compared to RMB 532.6 million in the same period of 2022[14] - The cell and gene therapy CTDMO business generated revenue of RMB 324.5 million, up 8.7% from RMB 298.6 million year-over-year[15] - Revenue from U.S. customers was RMB 5.41 billion, a 3% increase year-on-year, and a 22% increase when excluding COVID-19 commercialization projects[10] - Revenue from European customers grew by 19% year-on-year, reaching RMB 1.44 billion[10] Assets and Liabilities - Total assets as of March 31, 2023, amounted to RMB 68,188,088,624.62, a 5.41% increase from the end of the previous year[6] - The total liabilities as of March 31, 2023, were ¥18,357,086,099.46, compared to ¥17,763,654,011.21 at the end of 2022, representing a rise of approximately 3.3%[24] - The total current liabilities rose from 14,499,361 thousand RMB as of December 31, 2022, to 15,786,216 thousand RMB as of March 31, 2023, indicating an increase of approximately 8.87%[35] - The total equity attributable to shareholders increased to ¥49,474,882,627.12 from ¥46,589,953,393.31, showing a growth of approximately 6.3%[25] Business Operations and Strategy - The company serves over 6,000 active clients from more than 30 countries through 32 operational bases globally[4] - The workforce consists of 43,800 employees, with 13,147 holding master's degrees or higher, and 1,426 holding doctoral degrees[4] - The company continues to focus on talent retention through recruitment, training, and promotion to maintain high service standards and industry leadership[5] - The company added over 310 new customers in Q1 2023, bringing the total active customer count to over 6,000[10] - The company expects a revenue growth of 5-7% for the full year of 2023, based on current order status[17] - The company has completed IND applications for 175 projects and obtained CTA approvals for 150 projects as of the end of Q1 2023[16] - The company has developed a new drug for treating COVID-19, which has been approved for market launch in March 2023[16] - The company anticipates achieving approximately 50% compound growth rate in revenue from drug sales sharing agreements over the next decade[16] Research and Development - R&D expenses increased to RMB 357.30 million in Q1 2023, up from RMB 280.04 million in Q1 2022, representing a 27.6% rise[26] - The company has delivered over 260 ADC drug projects, establishing a comprehensive capability platform from early discovery to preclinical efficacy research[14] - The company is supporting 68 projects in the CTDMO service platform, including 52 preclinical and clinical phase I projects[15] - The new molecular-related revenue in the biology segment grew strongly by 40%, accounting for 25.3% of the total biology business revenue[14]

Financial Performance - In 2022, WuXi AppTec achieved a record revenue growth of 71.8% year-on-year, with total revenue reaching RMB 39,354.8 million compared to RMB 22,902.4 million in 2021[13]. - The adjusted net profit attributable to the parent company increased by 83.2% year-on-year, amounting to RMB 9,399.3 million, up from RMB 5,131.3 million in 2021[13]. - The gross profit margin improved to 36.9% in 2022, compared to 36.1% in the previous year[15]. - The company reported a net profit margin of 22.4% for the parent company, slightly up from 22.3% in 2021[15]. - The company achieved a revenue of RMB 39,354.8 million, representing a year-on-year growth of 71.8%[16]. - The net profit attributable to shareholders reached RMB 8,813.7 million, with a year-on-year increase of 72.9%[16]. - The company reported a net profit of RMB 8,902.6 million for 2022, a 73.3% increase from 2021, with a net profit margin rising from 22.4% to 22.6%[40]. - The company achieved a gross profit of RMB 14,506.5 million in 2022, an increase of 75.5% compared to the same period in 2021, with a main business gross profit of RMB 14,490.8 million and other business gross profit of RMB 15.7 million[26]. - The gross profit margin for the main business was 36.9%, up 0.8 percentage points from 2021[26]. Business Growth and Client Acquisition - WuXi AppTec's CRDMO and CTDMO business models continue to drive growth and meet increasing global customer demands[13]. - The company added over 1,400 new clients, serving more than 5,950 active clients from over 30 countries[16]. - Revenue from US clients was RMB 25,884 million, up 113% year-on-year; revenue from Chinese clients was RMB 7,526 million, up 30%[16]. - The chemical business (WuXi Chemistry) generated RMB 28,849.7 million, a 104.8% increase from RMB 14,087.2 million in 2021[18]. - The TIDES business saw a revenue increase of 337%, reaching RMB 1,578 million, with the number of service molecules growing by 91%[20]. Financial Stability and Assets - Total assets increased to RMB 64,690.3 million in 2022, up from RMB 55,127.4 million in 2021[15]. - The company maintained a debt-to-asset ratio of 27.5%, down from 29.7% in the previous year, indicating improved financial stability[15]. - The company’s cash and cash equivalents stood at RMB 7,983.9 million, compared to RMB 8,175.3 million in 2021[15]. - Total liabilities as of December 31, 2022, were RMB 17,763.7 million, an increase from RMB 16,369.9 million in 2021, with 40.8% attributed to accounts payable and other payables[43]. Research and Development - The company’s R&D expenses rose to RMB 1,614.0 million, a 71.3% increase from 2021, focusing on new molecular types such as PROTAC and gene therapy[35]. - The company aims to enhance its service capabilities for new molecular types such as PROTAC, oligonucleotide drugs, peptide drugs, and gene therapy, capturing new business opportunities[98]. Sustainability and ESG Commitment - The company emphasized its commitment to ESG principles, integrating them into all aspects of its operations[13]. - The company received silver certification from EcoVadis for sustainability ratings across its three bases in Changzhou, Shanghai, and Wuxi[20]. - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 30% by 2025[120]. Future Outlook and Guidance - For 2023, WuXi Chemistry expects revenue growth of 36-38%, while other segments anticipate a 20-23% increase, with WuXi DDSU projected to decline over 20%[24]. - The company is confident in its future development and maintaining its industry-leading position[13]. - The company expects adjusted non-IFRS gross profit to grow by 12-14% in 2023, contributing to the growth of adjusted non-IFRS profit attributable to equity holders[52]. Corporate Governance and Management - The management team possesses extensive industry experience and a strong international perspective, enabling the company to quickly adapt to market trends and client needs[73]. - The company has established a robust internal control system to ensure compliance with laws and regulations, but risks remain due to the complexity of managing multiple subsidiaries[104]. - The board consists of 13 members, including 6 executive directors, ensuring diverse leadership and strategic oversight[113]. Risks and Challenges - The company faces risks from a potential decline in demand for pharmaceutical R&D services, which could negatively impact business if industry trends slow down[101]. - Regulatory changes in the pharmaceutical R&D services industry pose a risk, requiring the company to adapt its strategies to comply with evolving policies[102]. - Increased competition in the global pharmaceutical R&D services market could threaten the company's competitive advantages if it fails to strengthen its R&D capabilities[103]. Shareholder Communication and Dividends - The company has established a shareholder communication policy to ensure proper responses to shareholder concerns and feedback[172]. - The company proposed a cash dividend of RMB 8.9266 per 10 shares for the year 2022, totaling RMB 2,644,137,750.80, compared to RMB 1,529,441,704.14 in 2021[176].

证券代码：603259 证券简称：药明康德 公告编号：临 2023-026 无锡药明康德新药开发股份有限公司 关于召开 2022 年度业绩说明会的公告 （一）会议召开时间：2023 年 4 月 13 日（星期四）上午 10:30-11:30 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已于 2023 年 3 月 21 日在上海证券交易所网站（www.sse.com.cn）及指定媒体披露《无锡药明康 德新药开发股份有限公司 2022 年年度报告》。为了便于广大投资者更全面深入地 了解本公司 2022 年度业绩和经营情况，本公司拟于 2023 年 4 月 13 日（星期四） 上午 10:30-11:30 召开业绩说明会，就投资者普遍关心的问题进行交流。 一、 业绩说明会类型 本次业绩说明会以视频结合网络互动方式召开，本公司将针对 2022 年度业 绩和经营情况与投资者进行交流，并在信息披露允许的范围内就投资者普遍关注 的问题进行回答。 二、业绩说明会召开的时 ...

Financial Performance - The company achieved a record revenue of RMB 39,354,777,805.53 in 2022, representing a growth of 71.84% compared to 2021[20]. - Net profit attributable to shareholders reached RMB 8,813,713,033.51, marking a 72.91% increase from the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 8,260,289,685.19, which is a 103.27% increase year-over-year[20]. - The net cash flow from operating activities was RMB 10,616,029,916.68, reflecting a significant increase of 131.32% compared to 2021[20]. - The company's total assets at the end of 2022 were RMB 64,690,326,746.96, up 17.35% from the previous year[20]. - Basic earnings per share for 2022 were RMB 3.01, an increase of 72.00% compared to 2021[21]. - The weighted average return on net assets was 20.62%, an increase of 6.57 percentage points from the previous year[21]. - The net profit attributable to shareholders increased by 72.91% year-on-year, while the net profit excluding non-recurring gains and losses grew by 103.27%[23]. - The net cash flow from operating activities reached RMB 1,061,602.99 million, a 131.32% increase compared to the same period in 2021[23]. - Basic earnings per share increased by 72.00%, diluted earnings per share rose by 63.01%, and basic earnings per share excluding non-recurring gains and losses grew by 102.88%[23]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 8.9266 per 10 shares, totaling RMB 2,644,137,750.80 for the year 2022[4]. - There are no significant changes in the total share capital prior to the dividend distribution date[4]. - The net profit attributable to ordinary shareholders of the listed company for the consolidated financial statements is RMB 8,813,713,033.51, with a dividend payout ratio of 30%[144]. - The profit distribution plan has been approved by all directors, including independent non-executive directors, and will be submitted for approval at the annual general meeting[142]. Operational Risks and Compliance - The company has confirmed that there are no significant risks that could materially affect its operations during the reporting period[6]. - The company has outlined potential risks in its operations, which are detailed in the report[6]. - The company has not faced any violations of decision-making procedures regarding external guarantees[5]. - The company has not disclosed any forward-looking commitments that could be construed as guarantees to investors[5]. - The company emphasizes compliance and has established a robust internal control system, but risks remain if oversight of subsidiaries is insufficient[94]. - The company faces risks from a potential decline in demand for pharmaceutical research services, which could negatively impact business if industry growth slows or outsourcing ratios decrease[91]. - Regulatory changes in the pharmaceutical research services industry could pose risks if the company fails to adapt its operational strategies to comply with new policies and regulations[92]. Business Growth and Customer Base - In 2022, the company added over 1,400 new customers, with active customers exceeding 5,950[31]. - Revenue from U.S. customers was RMB 25.884 billion, a 113% year-on-year increase; revenue from Chinese customers was RMB 7.526 billion, up 30%[31]. - Revenue from the top 20 global pharmaceutical companies reached RMB 18.421 billion, a 174% increase year-on-year[31]. - Revenue from existing customers amounted to RMB 37.781 billion, reflecting a 77% growth compared to the previous year[31]. - The company achieved a total revenue of RMB 36.736 billion from clients using multiple business units, marking an 87% increase[31]. Research and Development - R&D expenses increased by 71.29% to RMB 1,613,953,441.33, reflecting the company's commitment to innovation[48]. - The company is committed to advancing digital transformation and optimizing data utilization across various business departments[89]. - The company plans to strengthen its service capabilities in new molecular types such as PROTAC, oligonucleotide drugs, and gene therapy, leveraging cutting-edge technologies[88]. - The company is focused on expanding its market presence and enhancing its research and development capabilities[125]. Environmental Management - The company has established an environmental protection mechanism and is classified as a key pollutant discharge unit by environmental protection authorities[156]. - The total SO₂ emissions from the company were 0.162 tons, with a concentration of 1.0 mg/m³, well below the standard limit of 200 mg/m³[157]. - The total NOx emissions were 6.30 tons, with a concentration of 49.9 mg/m³, also below the standard limit of 200 mg/m³[157]. - The company has implemented a waste management program to supervise and manage the generation, collection, classification, labeling, recording, storage, transportation, and disposal of waste[169]. - The company has established partnerships with qualified waste disposal units for the safe handling of hazardous waste, including animal carcasses and contaminated materials[183]. Governance and Management - The board of directors and management have ensured the accuracy and completeness of the annual report[2]. - The company has a complete business system and operates independently from the actual controller, with no business dependencies or competition[102]. - The board of directors includes a diverse group of experienced professionals, ensuring robust governance and strategic oversight[107]. - The company has maintained a consistent governance structure with independent directors overseeing key decisions[119]. - The total pre-tax remuneration for the Chairman and CEO, Ge Li, was CNY 41.97 million in the reporting period[104]. Future Outlook - The company expects a revenue growth of 5-7% in 2023, with WuXi Chemistry projected to grow by 36-38% and other business segments expected to grow by 20-23%[45]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming to reach $1.875 billion[109]. - New product launches are expected to contribute an additional $300 million in revenue, with a focus on innovative solutions in the biotech sector[109]. - The company is exploring potential acquisitions to bolster its portfolio, with a budget of $500 million allocated for strategic investments[109].

Financial Performance - The company achieved a revenue of RMB 39,354.8 million for the year ended December 31, 2022, representing a year-on-year growth of 71.8%[4]. - The net profit attributable to shareholders was RMB 8,813.7 million, an increase of 72.9% compared to the previous year[4]. - The gross profit reached RMB 14,506.5 million, with a gross margin of 36.9%, slightly up from 36.1% in 2021[2]. - The adjusted net profit attributable to shareholders was RMB 9,399.3 million, marking an 83.2% increase from the previous year[2]. - The net profit for the year increased by 73.3% to RMB 8,902.6 million, with a net profit margin of 22.6%[28]. - Overall gross profit for the company increased by 75.5% to RMB 14,506.5 million in 2022, with a gross margin of 36.9%[16]. - The total comprehensive income for the year was RMB 9,195,719 thousand, compared to RMB 4,625,059 thousand in the previous year, indicating a growth of approximately 98%[116]. - The company reported a pre-tax profit of RMB 10,618,477 thousand for the year ended December 31, 2022[124]. - The total revenue for the year ended December 31, 2022, was RMB 39,354,778 thousand, representing an increase from RMB 22,902,385 thousand in the previous year, which is a growth of approximately 72%[115]. Revenue Breakdown - Revenue from US clients was RMB 25,884 million, a significant increase of 113% year-on-year[5]. - Revenue from new clients amounted to RMB 1,573 million, contributing to a total revenue from existing clients of RMB 37,781 million, which grew by 77%[5]. - The chemical business segment generated RMB 28,849.7 million, reflecting a remarkable growth of 104.8% year-on-year[7]. - The revenue from the top 20 global pharmaceutical companies was RMB 18,421 million, showing a substantial growth of 174% year-on-year[5]. - The TIDES business achieved a revenue of RMB 1.578 billion, representing a year-on-year growth of 337%, with the number of service molecules increasing by 91% to 189[9]. - The testing business generated revenue of RMB 5.719 billion, a 26.4% increase from RMB 4.525 billion in the same period last year, with laboratory analysis and testing services growing by 36.1%[10]. - The biology segment reported revenue of RMB 2.475 billion, up 24.7% from RMB 1.985 billion, with new molecular-related services growing by 90%[11]. - The cell and gene therapy CTDMO business achieved revenue of RMB 1.308 billion, a 27.4% increase from RMB 1.026 billion, with testing services growing by 36%[12]. Client and Market Expansion - The company added over 1,400 new clients, serving more than 5,950 active clients globally across 30 countries[4]. - The company is expanding its international presence with new bases planned in Singapore and a production facility underway in Middletown, Delaware, USA[62]. - The company hosted 7 online events during the reporting period, with a total registration of over 28,000 participants, including industry leaders and patients, focusing on major challenges and opportunities in the industry[63]. - The company completed 77 live broadcasts covering all five major business segments, reaching over 220,000 views across more than 20 countries and regions, including all 34 provincial-level administrative regions in China[63]. Investment and R&D - Research and development expenses rose by 71.3% to RMB 1,614.0 million in 2022, reflecting increased investment in new molecular types[23]. - The company plans to invest heavily in new molecular types such as PROTAC, oligonucleotide drugs, and gene therapy, aiming to enhance its service capabilities and seize new business opportunities[89]. - The company has established a comprehensive "end-to-end" drug development service platform, benefiting from the rapid growth of the global drug development outsourcing market[59]. - The company reported a total of 973 new molecules in its pipeline, including 1 commercialized molecule, with a cumulative total of 2,341 molecules, comprising 50 commercial projects and 57 in clinical phase III[9]. Financial Management and Liabilities - The company's net cash flow from operating activities for 2022 was RMB 10,229.7 million, an increase of 133.6% compared to 2021, driven by rapid revenue growth and improved operational efficiency[29]. - The net cash used in investing activities for 2022 was RMB 9,311.2 million, up 101.2% from 2021, primarily due to increased capital expenditures for projects in various cities and investments in joint ventures[30]. - The total liabilities as of December 31, 2022, amounted to RMB 17,763.7 million, up from RMB 16,369.9 million in 2021, with 40.8% being accounts payable and other payables[31]. - The debt-to-asset ratio as of December 31, 2022, was 27.5%, down from 29.7% in 2021, reflecting an increase in retained earnings and net assets[34]. - The company has no significant contingent liabilities as of December 31, 2022[34]. Dividend and Shareholder Returns - The company proposed a final dividend of RMB 8.9266 per 10 shares, subject to shareholder approval[3]. - The board proposed a profit distribution plan for the year ending December 31, 2022, with a cash dividend of RMB 8.9266 per 10 shares, totaling RMB 2,644,137,750.80 (including tax)[107]. - The proposed profit distribution plan for 2022 includes a total dividend payout of RMB 2,644,137,750.80, translating to a dividend of RMB 0.89266 per share, an increase from RMB 0.5174 per share in 2021[140]. Risks and Challenges - The company faces risks from potential declines in demand for pharmaceutical R&D services, which could negatively impact its business[92]. - Regulatory changes in the pharmaceutical R&D services industry pose a risk, as the company must adapt to evolving policies and regulations[93]. - Increased competition in the global pharmaceutical R&D services market could threaten the company's competitive advantages if it fails to enhance its R&D capabilities[94]. - The company is exposed to foreign exchange risk, particularly if the RMB appreciates significantly, which could increase costs and lead to a decrease in customer orders[99]. Corporate Governance - The board confirmed adherence to corporate governance codes, although there was a deviation regarding the separation of the roles of Chairman and CEO, which are currently held by the same individual[110]. - The audit committee, consisting of three independent non-executive directors, reviewed the financial statements and internal controls for the reporting period[112].